Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase NA 1

Status

Recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 18Other hematologic neoplasm 14CNS 8Plasma cell 6Genitourinary 4Sarcoma 3Dermatologic 2Tumor-Agnostic 1Thoracic 1Myeloid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 3Metastatic Hormone-Sensitive Prostate Cancer 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Leukapheresis × Genitourinary × Clear all
NCT07219147 2026-04-20

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

Phase 1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT05805371 2025-11-19

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

Phase 1 Recruiting
21 enrolled
Genitourinary

Prostatic Neoplasms

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Fred Hutchinson Cancer Center

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03532217 2022-08-05

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of Medicine

Phase 1 Completed
19 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡